antibody

Anti-p63

MBS684293

1 mL (Prediluted)

175 USD

monoclonal

rabbit

nonconjugated

[V22-E]

immunohistochemistry, immunohistochemistry - paraffin section

Antibody

Anti-p63

[p63]

[tumor protein 63 isoform 2; Tumor protein 63; tumor protein 63; tumor protein p63; Chronic ulcerative stomatitis protein; CUSP; Keratinocyte transcription factor KET; Transformation-related protein 63; TP63; Tumor protein p73-like; p73L; p40; p51]

[p63]

[TP63; TP63; AIS; KET; LMS; NBP; RHS; p40; p51; p63; EEC3; OFC8; p73H; p73L; SHFM4; TP53L; TP73L; p53CP; TP53CP; B(p51A); B(p51B); KET; P63; P73H; P73L; TP73L; p63; CUSP; TP63; p73L]

P63_HUMAN

Monoclonal

[V22-E]

Rabbit

Human

555

Storage: +4 degree C

Immunohistochemistry (IHC) Paraffin

Immunohistochemistry (IHC) Paraffin: 1:100 - 1:200

Immunohistochemistry (IHC)

Immunohistochemistry (IHC)

Buffer: 20 mM Tris-HCl, pH 8.0. Stabilizer: 20 mg/ml BSA

Preservative: 0.05% NaN3. Immunogen: Peptide derived from the internal sequence of human p63. Antibody recognizes the epitope between Tyr231 - Arg251. Cellular localization: nucleus. Positive control: tonsil tissue. IHC-P PROTOCOL: INSTRUCTION MANUAL. 1. Deparaffinize the section in 3 changes of xylene, 10 minutes each. 2. Wash the section in 96%, 80% and 70% ethyl alcohol for 10 minutes each. 3. Rinse in distilled water, 2 x 5 minutes. 4. Block the endogenous peroxidase by incubating the tissue in 3% hydrogen peroxide (H2O2) for 10 minutes. 5. Wash in distilled water, 2 x 5 minutes. 6. For antigen retrieval: Immerse the slide in Tris-EDTA buffer*, pH 9.0 and incubate at 95-97ºC in water bath for 25 minutes. 7. Remove the staining to room temperature and let the slide to cool (in Tris-EDTA buffer, pH 9.0) for 15 minutes. 8. Rinse in distilled water, 2 x 5 minutes. 9. Wash in PBS (phosphate buffer saline, pH 7.0-7.5) supplemented with 0.05% of Tween-20 (buffer A), 2 x 5 minutes. 10. CONCENTRATED: . Incubate the section with primary antibody at the dilution 1:100 - 1:200 for 1 hour in the closed wet chamber. READY TO USE (RTU):. Incubate the section with primary antibody (ready to use) for 1 hour in a closed wet chamber. 11. Wash 3 x 5 minutes with buffer A. 12. Apply the secondary antibody (the protocol depends on the supplier), and proceed3to standard immunohistochemistry protocol (HRP - Peroxide - DAB). Micropolymer-HRP detection kit rabbit/mouse dual is suggested. 13. Wash 3 x 5 minutes with buffer A. 14. Apply the chromogen (DAB), 1 - 3 minutes. 15. Wash in water, 2 x 5 minutes. 16. Stain in hematoxylin for 5 minutes. 17. Wash in distilled water, 3 x 2 minutes. 18. Mount the slide for observation. VENTANA PROTOCOL : INSTRUCTION MANUAL . SHORT APPLICATION PROTOCOL FOR VENTANA BENCHMARK SLIDE STAINING SYSTEM . 1. Deparafinization (Enter). 2. Heating glass (72oC) with the medium temperatures. Deparafinization. 3. Prolonged deparafinization (Enter). 4. Cell conditioning (Enter). 5. ULTRA Conditioner #2 (Enter). 6. Heating glass (97°C), incubation 8 min (Cell conditioner #2). 7. ULTRA CC2 solution application – 24 min (Enter). 8. Titration (Enter). 9. Hand apply – primary antibody. Incubation 32 min. 10. UltraWash (Enter). 11. Nuclear stain (Enter). 12. Hematoxylin application – one drop (nuclear stain). Cover and incubate 8 min. 13. After nuclear stain (Enter). 14. Bluing reagent application, one drop. After nuclear stain, cover and incubate 4 min. PRECAUTIONS: 1. Intended for professional In Vitro Diagnostic use in laboratories. 2. Do not use after expiration date stamped on vial label. 3. Avoid contamination of the reagent. 4. Any discrepancies in the recommended procedures stated in the working protocol may affect the final results. 5. The reagent contains sodium azide (NaN3) which is highly toxic in higher concentrations. The concentration in the reagent (0.05%) is not considered as hazardous. 6. Disposal of waste material must be conducted in accordance with local regulations. 7. Wear appropriate Personal Protective Equipment to avoid contact with eyes and skin.

169234657

NP_001108450.1

NM_001114978.1

Q9H3D4

65,288 Da

Apoptosis Pathway (198797); Direct P53 Effectors Pathway (137939); Gene Expression Pathway (1269649); Generic Transcription Pathway (1269650); MicroRNAs In Cancer Pathway (852705); MicroRNAs In Cancer Pathway (852928); TP53 Regulates Metabolic Genes Pathway (1269655); TP53 Network Pathway (198896); Transcriptional Regulation By TP53 Pathway (1269654)

This gene encodes a member of the p53 family of transcription factors. An animal model, p63 -/- mice, has been useful in defining the role this protein plays in the development and maintenance of stratified epithelial tissues. p63 -/- mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); split-hand/foot malformation 4 (SHFM4); ankyloblepharon-ectodermal defects-cleft lip/palate; ADULT syndrome (acro-dermato-ungual-lacrimal-tooth); limb-mammary syndrome; Rap-Hodgkin syndrome (RHS); and orofacial cleft 8. Both alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different proteins. Many transcripts encoding different proteins have been reported but the biological validity and the full-length nature of these variants have not been determined. [provided by RefSeq, Jul 2008]

p63: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. Binds DNA as a homotetramer. Isoform composition of the tetramer may determine transactivation activity. Isoforms Alpha and Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate coactivator activity. Isoform 1 and isoform 2 interact with WWP1. Interacts with PDS5A. Isoform 5 (via activation domain) interacts with NOC2L. Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues. Belongs to the p53 family. 12 isoforms of the human protein are produced by alternative promoter. Protein type: DNA-binding; Transcription factor. Chromosomal Location of Human Ortholog: 3q28. Cellular Component: cytoplasm; cytosol; dendrite; nuclear chromatin; nucleoplasm; nucleus; rough endoplasmic reticulum; transcription factor complex. Molecular Function: chromatin binding; damaged DNA binding; DNA binding; double-stranded DNA binding; identical protein binding; metal ion binding; p53 binding; protein binding; sequence-specific DNA binding; transcription factor activity; WW domain binding. Biological Process: apoptosis; chromatin remodeling; cloacal septation; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; ectoderm and mesoderm interaction; embryonic limb morphogenesis; epidermal cell division; epithelial cell development; establishment of planar polarity; female genitalia morphogenesis; G1 DNA damage checkpoint; gene expression; hair follicle morphogenesis; keratinocyte differentiation; keratinocyte proliferation; multicellular organismal aging; negative regulation of apoptosis; negative regulation of keratinocyte differentiation; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; neuron apoptosis; Notch signaling pathway; odontogenesis of dentine-containing teeth; polarized epithelial cell differentiation; positive regulation of mesenchymal cell proliferation; positive regulation of Notch signaling pathway; positive regulation of osteoblast differentiation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; protein homotetramerization; proximal/distal pattern formation; regulation of caspase activity; regulation of epidermal cell division; regulation of neuron apoptosis; replicative cell aging; response to DNA damage stimulus; response to gamma radiation; response to X-ray; skeletal development; skin morphogenesis; smooth muscle development; spermatogenesis; sympathetic nervous system development; transcription initiation from RNA polymerase II promoter; urinary bladder development. Disease: Adult Syndrome; Ankyloblepharon-ectodermal Defects-cleft Lip/palate; Ectrodactyly, Ectodermal Dysplasia, And Cleft Lip/palate Syndrome 3; Limb-mammary Syndrome; Rapp-hodgkin Syndrome; Split-hand/foot Malformation 4

1 mL (Prediluted)

175 USD

0.04 mL (Concentrate)

185

0.1 mL (Concentrate)

345

7 mL (Prediluted)

370

0.2 mL (Concentrate)

470

15 mL (Prediluted)

545

0.5 mL (Concentrate)

590

1 mL (Concentrate)

905